the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
September 22, 2016 – The pharmacologically active compound known as sildenafil is largely used to treat erectile dysfunction (on the market for this indication under the trade name Viagra) and pulmonary arterial hypertension (on the market for this indication under the trade name Revatio) in …
September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy option which gives much hope for at least some of the affected patients. However, be …
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved Read more »
September 17, 2016 – Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012. In Europe, there were an estimated 464,000 new cases of breast cancer in 2012 and an estimated 131,000 …
Palbociclib (Ibrance): New treatment for advanced or metastatic breast cancer in the EU Read more »
August 01, 2016 – Type 2 diabetes affects more than 29 million people and accounts for more than 90 percent of diabetes cases diagnosed in the United States. Over time, high blood sugar levels can increase the risk for serious …
Lixisenatide (Adlyxin) approved to treat type 2 diabetes Read more »
June 29, 2016 – The saga goes on: The American Food & Drug Administration (FDA) just approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) infection both with and without cirrhosis (advanced liver disease). For patients with …
June 22, 2016 – The European Medicines Agency (EMA) has approved, as of the end of May 2016, Infliximab (Flixabi). Infliximab (Flixabi) is a monoclonal antibody that has been designed to attach to a protein called tumour necrosis factor-alpha (TNF-alpha) and block …
May 30, 2016 – According to its News and Events section of the homepage, the European Medicines Agency (EMA) has recommended the granting of marketing authorisations in the European Union (EU) for two new combination therapies against chronic (long-term) hepatitis C virus (HCV) infection, namely …
EMA: Two new combination therapies against chronic hepatitis C recommended for approval Read more »
May 28, 2016 – Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body. It is among the most common causes of neurological disability in …
Daclizumab (Zinbryta) approved for the treatment of multiple sclerosis (MS) Read more »
May 18, 2016 – Over the last two years, biologics targeting the PD-1/PD-L1 pathway (proteins found on the body’s immune cells and some cancer cells), notably Nivolumab (Opdivo) and Pembrolizumab (Keytruda), have come to the clinic for the treatment of a selection of …
Hope for patients with urothelial carcinoma: Atezolizumab (Tecentriq) approved Read more »
April 29, 2016 – The American Food and Drug Administration (FDA) has approved Pimavanserin (Nuplazid), the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s disease. Pimavanserin (Nuplazid) acts as an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and …